Literature DB >> 36065277

Assessing the Emergence of Resistance in vitro and Invivo: Linezolid Combined with Fosfomycin Against Fosfomycin-Sensitive and Resistant Enterococcus.

Yaowen Li1,2, Yu Peng1,2, Na Zhang1,2, Huiping Liu1,2, Jun Mao1,2, Yisong Yan3, Shuaishuai Wang1,2, Guang Yang4, Yanyan Liu5, Jiabin Li5, Xiaohui Huang1,2.   

Abstract

Purpose: We aimed to evaluate the synergistic effect of linezolid and fosfomycin on fosfomycin-sensitive and -resistant Enterococcus clinical isolates in vitro and in vivo and whether the emergence of fosfomycin resistance in Enterococcus is associated with changes in strain virulence, from the perspective of fitness cost.
Methods: The synergistic effect of linezolid and fosfomycin was studied via in vitro checkerboard and static time-kill assays, as well as based on the in vivo survival rate and hemolymph load of a Galleria mellonella infection model. Fosfomycin resistance was induced via a stepwise increase in concentration. Changes in the virulence of the strains after drug resistance were investigated using the G. mellonella infection model and reverse transcription quantitative polymerase chain reaction (RT-qPCR). In vitro and in vivo growth curves and competitive experiments were used to study the fitness cost of the strain. Finally, a static time-kill assay was performed to explore the effect of the combined medication.
Results: In vitro and in vivo data showed that linezolid combined with fosfomycin had a good synergistic effect on Enterococcus treatment. The G. mellonella infection model and RT-qPCR data showed that the virulence of the resistant strains was weakened to varying degrees. A survival curve and competition experimental data showed that this was related to the fitness cost of strains while acquiring resistance and negatively impacted linezolid treatment; however, the combination still showed a good synergistic effect in drug-resistant strains.
Conclusion: Linezolid combined with fosfomycin had a synergistic effect on both fosfomycin-sensitive and -resistant Enterococcus strains. Strains incur fitness costs as they develop drug resistance, which leads to a decrease in virulence. There is an interaction between fitness cost, virulence, and drug resistance, which indirectly affects drug treatment.
© 2022 Li et al.

Entities:  

Keywords:  fitness cost; fosfomycin; linezolid; resistance; virulence

Year:  2022        PMID: 36065277      PMCID: PMC9440711          DOI: 10.2147/IDR.S377848

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.177


  72 in total

1.  Survival of Patients With Vancomycin-Resistant Enterococcus faecium Bacteremia Treated With Conventional or High Doses of Daptomycin or Linezolid Is Associated With the Rate of Bacterial Clearance.

Authors:  Yu-Chung Chuang; Hsin-Yi Lin; Pao-Yu Chen; Chi-Ying Lin; Yee-Chun Chen; Jann-Tay Wang; Shan-Chwen Chang
Journal:  Crit Care Med       Date:  2018-10       Impact factor: 7.598

2.  Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic.

Authors:  Karen L Nielsen; Thomas M Pedersen; Klas I Udekwu; Andreas Petersen; Robert L Skov; Lars H Hansen; Diarmaid Hughes; Niels Frimodt-Møller
Journal:  J Antimicrob Chemother       Date:  2012-02-29       Impact factor: 5.790

3.  Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Authors:  Lauren M Boak; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

4.  Synergistic activity of fosfomycin and chloramphenicol against vancomycin-resistant Enterococcus faecium (VREfm) isolates from bloodstream infections.

Authors:  Cristina Lagatolla; Johana Milic; Francesco Imperi; Matteo Cervoni; Raffaela Bressan; Roberto Luzzati; Stefano Di Bella
Journal:  Diagn Microbiol Infect Dis       Date:  2020-10-15       Impact factor: 2.803

5.  In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model.

Authors:  Lara Thieme; Anita Hartung; Oliwia Makarewicz; Mathias W Pletz
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

Review 6.  The Enterococcus: a Model of Adaptability to Its Environment.

Authors:  Mónica García-Solache; Louis B Rice
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

7.  Spread of Linezolid-Resistant Enterococcus spp. in Human Clinical Isolates in the Czech Republic.

Authors:  Lucia Mališová; Vladislav Jakubů; Katarína Pomorská; Martin Musílek; Helena Žemličková
Journal:  Antibiotics (Basel)       Date:  2021-02-22

Review 8.  Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years.

Authors:  Ling-Ling Zhu; Quan Zhou
Journal:  Infect Drug Resist       Date:  2018-08-08       Impact factor: 4.003

9.  Generous hosts: Why the larvae of greater wax moth, Galleria mellonella is a perfect infectious host model?

Authors:  Nabil Killiny
Journal:  Virulence       Date:  2018-12-31       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.